Lupus erythematosus - Lupus Eritematosa
☆ AI Dermatology — Free Service
Alemaniako Stiftung Warentest-en 2022ko emaitzetan, ModelDerm-ekin kontsumitzaileen gogobetetasuna apur bat txikiagoa izan zen ordaindutako telemedikuntzako kontsultekin baino.
Alemaniako Stiftung Warentest-en 2022ko emaitzetan, ModelDerm-ekin kontsumitzaileen gogobetetasuna apur bat txikiagoa izan zen ordaindutako telemedikuntzako kontsultekin baino.
Eritema purpura samarra bezala agertzen da.
Aurpegian normalean agertzen den tximeleta erupzioa da.
relevance score : -100.0%
ReferencesCutaneous lupus erythematosus (CLE) identifikatzeak eta sailkatzeak diagnostiko erronkak dakartza, larruazaleko inplikazioarekin systemic lupus erythematosus-etatik bereiziz. Azken ikerketek CLEren azpian dauden faktore genetikoak, ingurumenekoak eta immunologikoak argitzen dituzte. Droga-indukzioa bereziki CLEren abiarazle garrantzitsuenetako bat bezala agertu da. Tratamenduak terapia topiko eta sistemikoak hartzen ditu, eta belimumab, rituximab, ustekinumab, anifrolumab, eta BIIB059 bezalako biologiko itxaropentsuak barne, saiakuntza klinikoetan eraginkortasuna frogatua dutenak.
Diagnostic challenges exist in better defining cutaneous lupus erythematosus (CLE) as an independent disease distinct from systemic lupus erythematosus with cutaneous features and further classifying CLE based on clinical, histological, and laboratory features. Recent mechanistic studies revealed more genetic variations, environmental triggers, and immunologic dysfunctions that are associated with CLE. Drug induction specifically has emerged as one of the most important triggers for CLE. Treatment options include topical agents and systemic therapies, including newer biologics such as belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 that have shown good clinical efficacy in trials.
Diagnostic challenges exist in better defining cutaneous lupus erythematosus (CLE) as an independent disease distinct from systemic lupus erythematosus with cutaneous features and further classifying CLE based on clinical, histological, and laboratory features. Recent mechanistic studies revealed more genetic variations, environmental triggers, and immunologic dysfunctions that are associated with CLE. Drug induction specifically has emerged as one of the most important triggers for CLE. Treatment options include topical agents and systemic therapies, including newer biologics such as belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 that have shown good clinical efficacy in trials.
Cutaneous lupus erythematosus (CLE) azaleko hainbat arazo biltzen ditu, eta horietako batzuk osasun arazo zabalagoekin lotu daitezke. Mota ezberdinetan sailkatuta dago, hala nola acute CLE (ACLE), sub-acute CLE (SCLE) eta chronic CLE (CCLE). CCLE, discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus eta lupus tumidus osatzen dute.
Cutaneous lupus erythematosus (CLE) encompasses a wide range of dermatologic manifestations, which may or may not be associated with the development of systemic disease. Cutaneous lupus is divided into several sub-types, including acute CLE (ACLE), sub-acute CLE (SCLE) and chronic CLE (CCLE). CCLE includes discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus and lupus tumidus.
Cutaneous lupus erythematosus (CLE) encompasses a wide range of dermatologic manifestations, which may or may not be associated with the development of systemic disease. Cutaneous lupus is divided into several sub-types, including acute CLE (ACLE), sub-acute CLE (SCLE) and chronic CLE (CCLE). CCLE includes discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus and lupus tumidus.
Lupus erythematosus gorputzaren atal ezberdinei eragin diezaiekeen gaixotasun autoimmuneen multzoa da. Mota batzuek, adibidez systemic lupus erythematosus (SLE), hainbat organotan eragiten dute; beste batzuek, cutaneous lupus erythematosus (CLE) bezalakoak, batez ere larruazalean eragiten dute. Seinale klinikoen, ehunen azterketaren eta odol‑analisen nahasketan oinarrituta sailkatzen ditugu CLE mota desberdinak, baina aldakuntza asko daude pertsonen artean. Larruazaleko arazoak maiz sortzen dira eguzki‑argia, erretzea edo zenbait botika bezalako faktoreengatik.
Lupus erythematosus comprises a spectrum of autoimmune diseases that may affect various organs (systemic lupus erythematosus [SLE]) or the skin only (cutaneous lupus erythematosus [CLE]). Typical combinations of clinical, histological and serological findings define clinical subtypes of CLE, yet there is high interindividual variation. Skin lesions arise in the course of triggers such as ultraviolet (UV) light exposure, smoking or drugs
Lupus erythematosus comprises a spectrum of autoimmune diseases that may affect various organs (systemic lupus erythematosus [SLE]) or the skin only (cutaneous lupus erythematosus [CLE]). Typical combinations of clinical, histological and serological findings define clinical subtypes of CLE, yet there is high interindividual variation. Skin lesions arise in the course of triggers such as ultraviolet (UV) light exposure, smoking or drugs
Lupus eritematosa (lupus erythematosus) -aren kausa ez dago argi. Biki berdinen artean, bat kaltetuta badago, %24 aukera dago bestea ere izateko. Emakumezkoen sexu hormonek, eguzki-argiak, erretzeak, D bitamina gabeziak eta zenbait infekzio arriskua areagotzen dutela uste da.
Tratamenduak NSAIDak, kortikoideak, immunosupresoreak, hydroxychloroquine (hidroxiklorokina) eta methotrexate (metotrexatoa) izan daitezke. Kortikoideak eraginkorrak diren arren, epe luzerako erabilerak bigarren mailako efektuak eragiten ditu.